Conclusion
We experienced a case of EDKA in a patient with T2DM on a
very-low-carbohydrate diet who developed EDKA within 3 days of receiving
SGLT2i. At present, SGLT2i are used not only for diabetes but also for
various diseases such as chronic kidney disease and heart failure.
SGLT2i will be used increasingly. When initiating SGLT2i, healthcare
providers should confirm the implementation of a low- or
very-low-carbohydrate diet and provide intensive guidance on preventing
the development of EDKA.